SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-21-140758
Filing Date
2021-04-29
Accepted
2021-04-29 17:03:02
Documents
5
Period of Report
2021-06-17

Document Format Files

Seq Description Document Type Size
1 DEF 14A d122001ddef14a.htm DEF 14A 295235
2 GRAPHIC g122001dsp001.jpg GRAPHIC 121702
3 GRAPHIC g122001dsp002.jpg GRAPHIC 122309
4 GRAPHIC g122001g09q52.jpg GRAPHIC 27424
5 GRAPHIC g122001g32d32.jpg GRAPHIC 41826
  Complete submission text file 0001193125-21-140758.txt   720950
Mailing Address 2280 INWOOD ROAD DALLAS TX 75235
Business Address 2280 INWOOD ROAD DALLAS TX 75235 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39536 | Film No.: 21871826
SIC: 2836 Biological Products, (No Diagnostic Substances)